Published in Eur Respir J on February 01, 2000
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
The lung in the antiphospholipid syndrome. Ann Rheum Dis (2002) 1.33
Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med (2006) 1.20
Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS One (2010) 0.97
Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol (2012) 0.95
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline. Can Respir J (2010) 0.92
Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One (2012) 0.86
Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol (2014) 0.85
Evaluation of patients with chronic thromboembolic pulmonary hypertension for pulmonary endarterectomy. Pulm Circ (2012) 0.83
Perfusion techniques for pulmonary thromboendarterectomy under deep hypothermia circulatory arrest: a case series. J Extra Corpor Technol (2006) 0.80
Coagulation and the vessel wall in pulmonary embolism. Pulm Circ (2013) 0.79
Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ (2016) 0.79
Chronic thromboembolic pulmonary hypertension. Curr Treat Options Cardiovasc Med (2010) 0.78
Fibrinogen Aα Thr312Ala polymorphism specifically contributes to chronic thromboembolic pulmonary hypertension by increasing fibrin resistance. PLoS One (2013) 0.77
Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension. Int J Mol Med (2013) 0.76
Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension. Open Respir Med J (2009) 0.76
Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms. Methodist Debakey Cardiovasc J (2017) 0.75
Chronic thromboembolic pulmonary hypertension and upper limb thrombosis. Eur Respir J (2000) 0.75
Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor? Clinics (Sao Paulo) (2010) 0.75
Reply to comments and questions of Dr. Correale et al. about our review concerning CTEPH. Neth Heart J (2015) 0.75
The flare up of catastrophic antiphospholipid syndrome: a report of an immunosuppressive withdrawal-induced case. Iran J Med Sci (2011) 0.75
Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool? Intractable Rare Dis Res (2017) 0.75
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med (1994) 7.17
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 7.08
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med (1995) 6.97
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Multiple essential functions of neuregulin in development. Nature (1995) 5.66
Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. N Engl J Med (1997) 5.17
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Ultrafast bond softening in bismuth: mapping a solid's interatomic potential with X-rays. Science (2007) 2.84
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
CYP98A3 from Arabidopsis thaliana is a 3'-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway. J Biol Chem (2001) 2.32
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
Common-sense models of illness: the example of hypertension. Health Psychol (1985) 2.26
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med (2000) 2.25
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Primary pulmonary hypertension and fenfluramine use. Br Heart J (1993) 2.02
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol (1995) 1.91
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood (1996) 1.89
Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost (2005) 1.88
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem (1984) 1.83
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
Congenital upper eyelid eversion complicated by corneal perforation. Br J Ophthalmol (2005) 1.73
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest (1999) 1.70
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood (2001) 1.69
Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest (1976) 1.67
Evidence that the Ya and Yc subunits of glutathione transferase B (ligandin) are the products of separate genes. Eur J Biochem (1982) 1.65
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Cost-effectiveness of strategies to enhance mammography use. Eff Clin Pract (2001) 1.65
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol (2001) 1.65
A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother (1997) 1.64
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest (1992) 1.62
Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost (2001) 1.60
The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev (2009) 1.60
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost (1995) 1.58
Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg (1999) 1.56
Double lung transplantation in situs inversus with Kartagener's syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg (1994) 1.53
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 1.51
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med (2000) 1.51
Agriculture. Transforming U.S. agriculture. Science (2011) 1.51
International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost (1993) 1.51
Academic stress, power motivation, and decrease in secretion rate of salivary secretory immunoglobulin A. Lancet (1983) 1.49
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost (2000) 1.48
Diagnosis and management of subsegmental pulmonary embolism. J Thromb Haemost (2006) 1.47
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med (1995) 1.46
Pulmonary vascular disorders in portal hypertension. Eur Respir J (1998) 1.44
Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. J Clin Microbiol (1998) 1.42
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax (2004) 1.40
[Lung transplantation]. Presse Med (1989) 1.39
Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. Eur Respir Rev (2009) 1.39
Management of severe pulmonary arterial hypertension. Eur Respir Rev (2010) 1.38
A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr (2007) 1.38
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest (1994) 1.38
[Nononcologic abdominal surgery in the elderly]. Chirurg (2005) 1.38
Cutaneous necrosis associated with acquired severe protein S deficiency. Thromb Haemost (1993) 1.37
Long-term follow-up of Stargardt's disease and fundus flavimaculatus. Ophthalmology (1998) 1.37
Pulmonary veno-occlusive disease. Eur Respir J (2009) 1.37
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Long term imatinib treatment in pulmonary arterial hypertension. Thorax (2006) 1.32